{{Rsnum
|rsid=4562389
|Gene=PTPRD
|Chromosome=9
|position=8805462
|Orientation=plus
|GMAF=0.3421
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 46.9 | 41.6 | 11.5
| HCB | 57.9 | 38.3 | 3.8
| JPT | 36.6 | 50.0 | 13.4
| YRI | 10.9 | 51.7 | 37.4
| ASW | 19.3 | 52.6 | 28.1
| CHB | 57.9 | 38.3 | 3.8
| CHD | 66.0 | 30.2 | 3.8
| GIH | 47.5 | 42.6 | 9.9
| LWK | 26.6 | 43.1 | 30.3
| MEX | 58.9 | 32.1 | 8.9
| MKK | 26.9 | 51.9 | 21.2
| TSI | 59.8 | 34.3 | 5.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4562389
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109451
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4562389
|overall_frequency_n=77
|overall_frequency_d=124
|overall_frequency=0.620968
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}